On June 24, 2013, a 60-second television advertisement will debut promoting BOTOX® (onabotulinumtoxinA) as a prophylactic treatment for adult patients living with Chronic Migraine (defined as experiencing 15 or more headache days per month, each lasting 4 hours a day or more).1
Important Limitations
Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies.
We’d like to emphasize that BOTOX® and BOTOX® Cosmetic (onabotulinumtoxinA) are FDA approved for different uses, different injection sites, and different dosages. It is important to understand that BOTOX® for appropriate Chronic Migraine patients is for those patients who are diagnosed as having ≥ 15 headache days per month with headache lasting 4 hours a day or longer, and that only BOTOX® can be used and reimbursed by insurance providers for this indication.
Allergan looks forward to our continued support of your practice with BOTOX® Cosmetic and the entire Allergan Medical portfolio of products.
Lynn Salo
Vice President
Sales & Marketing—Facial Aesthetics
Click here for the announcement.
By Sydney Gatta, RN In the realm of facial aesthetics and rejuvenation, innovative treatments continue to emerge, offering patients a plethora of options to
By Arianna Bankovich, RN Introduction: Botox, derived from the bacterium Clostridium botulinum, has long been renowned for its cosmetic applications in reducing wrinkles and fine
By Crystal Wilson, CNP In the dynamic landscape of healthcare, career trajectories often take unexpected turns. One noticeable trend in recent years is the increasing